Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 8:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 8,511 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Control Group Clear all
Terminated Phase 2 Interventional Results available

A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus

NCT01792635
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-05175157, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Oct 24, 2026, 8:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Video Counseling: A Randomized Control Trial

NCT04300725
View directory record Official record
Conditions
Pregnancy Related
Interventions
Video Counseling
Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 24, 2026, 8:56 PM EDT
Completed Phase 2 Interventional Results available

ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)

NCT05279417
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ATI-450 50 mg oral tablet BID, Placebo oral tablet, Methotrexate, ATI-450 20 mg oral tablet BID
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
11
States / cities
El Cajon, California • Encino, California • La Jolla, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 24, 2026, 8:56 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

NCT06007690
View directory record Official record
Conditions
Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
Interventions
Bel-sar, Suprachoroidal Microinjector, Infrared Laser, Sham Infrared Laser, Sham Microinjector
Drug · Device
Lead sponsor
Aura Biosciences
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
25
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 24, 2026, 8:56 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia

NCT03056690
View directory record Official record
Conditions
Fibromyalgia
Interventions
ASP0819, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
24
States / cities
Birmingham, Alabama • El Cajon, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 24, 2026, 8:56 PM EDT
Active, not recruiting Not applicable Interventional

The Group Risk Reduction Intervention Therapy (GRRIT) Project

NCT05401838
View directory record Official record
Conditions
Suicidal Ideation, Suicide, Attempted, Coping Skills, Depression, Anxiety, PTSD
Interventions
Group Brief Cognitive-Behavioral Therapy (G-BCBT), Dialectical Behavior Therapy (DBT) Skills Group
Behavioral
Lead sponsor
University of North Carolina, Charlotte
Other
Eligibility
18 Years to 99 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 24, 2026, 8:56 PM EDT
Completed Phase 3 Interventional Results available

A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain

NCT01539538
View directory record Official record
Conditions
Post-Operative Pain
Interventions
Sufentanil NanoTab PCA System/15 mcg, morphine IV PCA
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
16
States / cities
Florence, Alabama • Montgomery, Alabama • Sheffield, Alabama + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Oct 24, 2026, 8:56 PM EDT
Completed Phase 3 Interventional

Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients

NCT05586958
View directory record Official record
Conditions
Gout, Hyperuricemia, Gout Flare, Tophi
Interventions
Tigulixostat, Placebo
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 85 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
36
States / cities
Birmingham, Alabama • Covina, California • Clearwater, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 24, 2026, 8:56 PM EDT
Completed Phase 4 Interventional Results available

8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension

NCT00809926
View directory record Official record
Conditions
Stage 2 Hypertension
Interventions
Valsartan/aliskiren, Valsartan
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 2, 2011 · Synced Oct 24, 2026, 8:56 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Capacity Builders Inc. Navajo Youth Builders Personal Responsibility Education Innovation Strategies Project

NCT04180358
View directory record Official record
Conditions
Sexual Abstinence, Responsible Sex
Interventions
Native STAND, Regular Health/Physical Education Curriculum
Behavioral
Lead sponsor
Capacity Builders Inc.
Other
Eligibility
14 Years to 18 Years
Enrollment
834 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Farmington, New Mexico
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 24, 2026, 8:56 PM EDT
Completed Phase 2 Interventional

A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome

NCT01894958
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
NNZ-2566, Placebo
Drug
Lead sponsor
Neuren Pharmaceuticals Limited
Industry
Eligibility
12 Years to 45 Years · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Sacramento, California • Denver, Colorado • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 24, 2026, 8:56 PM EDT
Completed Not applicable Interventional Results available

Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications

NCT02694185
View directory record Official record
Conditions
Myocardial Ischemia, Rheumatic Diseases
Interventions
Caplan IVR
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 95 Years
Enrollment
5,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
4
States / cities
San Francisco, California • Aurora, Colorado • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 24, 2026, 8:56 PM EDT
Recruiting Not applicable Interventional

Neurofeedback and Well-Being Among People With Co-Occurring Obsessive Compulsive Disorder and Post-traumatic Stress Symptoms

NCT07217925
View directory record Official record
Conditions
Well-Being, Psychological, Mood Disturbance, Emotional Regulation, Dissociation, Post Traumatic Stress Symptoms
Interventions
Neuroptimal (Zengar, Inc.) Neurofeedback
Device
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 24, 2026, 8:56 PM EDT
Completed Not applicable Interventional

Ultrasound Guided Arthrocentesis

NCT00537589
View directory record Official record
Conditions
Arthritis, Joint Pain
Interventions
Ultrasound guided arthrocentesis
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 24, 2026, 8:56 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo

NCT02284568
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis
Interventions
Placebo, Laquinimod
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
25 Years to 55 Years
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
Phoenix, Arizona • Newport Beach, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 24, 2026, 8:56 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Modulation of Human Myocardial Metabolism by GLP-1 Dose Response

NCT01607450
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Healthy
Interventions
GLP-1 Low Dose, GLP-1 Mid-Range Dose, GLP-1 High Dose, Saline
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 24, 2026, 8:56 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit

NCT00832650
View directory record Official record
Conditions
Healthy
Interventions
fesoterodine fumarate, placebo, solifenacin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 24, 2010 · Synced Oct 24, 2026, 8:56 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation Of PF-00572778 And Alprazolam On Naloxone Challenge In Healthy Subjects

NCT00580190
View directory record Official record
Conditions
Healthy
Interventions
alprazolam, Placebo, PF-00572778
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 14, 2009 · Synced Oct 24, 2026, 8:56 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Effects of Itopride on Gastric Motor and Sensory Functions in Healthy Volunteers

NCT00370110
View directory record Official record
Conditions
Healthy
Interventions
Itopride 100 mg, Placebo, Itopride 200 mg
Drug · Other
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 24, 2026, 8:56 PM EDT
Completed Not applicable Interventional Results available

Kidpower Camp - Structured Games or Playgroup

NCT04960813
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Structured games, Playgroup
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
48 Months to 71 Months
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Ann Arbor, Michigan • East Lansing, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 24, 2026, 8:56 PM EDT
Terminated Phase 3 Interventional Results available

Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension.

NCT00315458
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch, Placebo transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
48
States / cities
Birmingham, Alabama • Haleyville, Alabama • Muscle Shoals, Alabama + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 24, 2026, 8:56 PM EDT
Completed Phase 4 Interventional

Multimodal Analgesia Effect on Post Surgical Patient

NCT04240626
View directory record Official record
Conditions
Obesity, Morbid, Surgery, Bariatric Surgery Candidate
Interventions
Neurontin, Dilaudid Injectable Product, Marcaine Injectable Product, Oxycodone Hydrochloride, Hycet 7.5Mg-325Mg/15Ml Solution, Zofran Injection, Scopolamine patch, Ativan, Flexeril Oral Product, Tylenol Suspension
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
35 Years to 65 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 24, 2026, 8:56 PM EDT
Completed Phase 1 Interventional

The Effect of Action Control Based Intervention on Adherence After Cardiac Rehabilitaiton

NCT00602485
View directory record Official record
Conditions
Heart Failure
Interventions
Action Control Education
Other
Lead sponsor
Summa Health System
Other
Eligibility
21 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2009 · Synced Oct 24, 2026, 8:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Hydrocortisone in Patients With Post-Traumatic Stress Disorder

NCT00039715
View directory record Official record
Conditions
Post-Traumatic Stress Disorders, Healthy
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 24, 2026, 8:56 PM EDT